Last reviewed · How we verify
Ipilimumab IT
At a glance
| Generic name | Ipilimumab IT |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (PHASE2)
- A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (PHASE1, PHASE2)
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE2)
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer (PHASE2)
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. (PHASE1, PHASE2)
- CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (PHASE2)
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ipilimumab IT CI brief — competitive landscape report
- Ipilimumab IT updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI